MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
PR Newswire —
TAINAN, Feb. 9, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's disease (AD). The study demonstrated that...